SG11202000054RA - Bispecific anti pd1-anti tim3 antibodies - Google Patents

Bispecific anti pd1-anti tim3 antibodies

Info

Publication number
SG11202000054RA
SG11202000054RA SG11202000054RA SG11202000054RA SG11202000054RA SG 11202000054R A SG11202000054R A SG 11202000054RA SG 11202000054R A SG11202000054R A SG 11202000054RA SG 11202000054R A SG11202000054R A SG 11202000054RA SG 11202000054R A SG11202000054R A SG 11202000054RA
Authority
SG
Singapore
Prior art keywords
bispecific
tim3 antibodies
antibodies
bispecific anti
tim3
Prior art date
Application number
SG11202000054RA
Other languages
English (en)
Inventor
Cecilia Anna Wilhelmina Geuijen
Rinse Klooster
Kruif Cornelis Adriaan De
Paulus Johannes Tacken
Mark Throsby
Ton Logtenberg
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of SG11202000054RA publication Critical patent/SG11202000054RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11202000054RA 2017-07-06 2018-07-06 Bispecific anti pd1-anti tim3 antibodies SG11202000054RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17180061 2017-07-06
PCT/NL2018/050450 WO2019009727A1 (en) 2017-07-06 2018-07-06 ANTI-PD1 ANTI-TIM3 BISPECIFIC ANTIBODIES

Publications (1)

Publication Number Publication Date
SG11202000054RA true SG11202000054RA (en) 2020-02-27

Family

ID=59366222

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202000054RA SG11202000054RA (en) 2017-07-06 2018-07-06 Bispecific anti pd1-anti tim3 antibodies

Country Status (15)

Country Link
US (2) US11753470B2 (de)
EP (1) EP3649155A1 (de)
JP (1) JP7422655B2 (de)
KR (1) KR20200042467A (de)
CN (1) CN111094348A (de)
AU (1) AU2018297058B2 (de)
BR (1) BR112020000227A2 (de)
CA (1) CA3068932A1 (de)
EA (1) EA202090004A1 (de)
IL (1) IL271832A (de)
MX (1) MX2020000055A (de)
PH (1) PH12020550013A1 (de)
SG (1) SG11202000054RA (de)
TW (1) TW201920657A (de)
WO (1) WO2019009727A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3649156A1 (de) * 2017-07-06 2020-05-13 Merus N.V. Antikörper zur modulation einer durch eine zelle exprimierten biologischen aktivität
TWI804572B (zh) * 2018-02-09 2023-06-11 日商小野藥品工業股份有限公司 雙特異性抗體
MX2020010267A (es) * 2018-03-30 2020-11-06 Merus Nv Anticuerpo multivalente.
EP3966247A4 (de) * 2019-05-06 2023-01-04 Brown University Bispezifische antikörper gegen chi3l1 und pd1 mit verbesserten t-zell-vermittelten zytotoxischen wirkungen auf tumorzellen
SG11202112399PA (en) 2019-05-09 2021-12-30 Merus Nv Variant domains for multimerizing proteins and separation thereof
CN113563473A (zh) * 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
AR127714A1 (es) * 2021-11-19 2024-02-21 Merus Nv UNIDADES DE UNIÓN MULTIESPECÍFICAS QUE COMPRENDEN LOS DOMINIOS DE UNIÓN A PD-1 Y TGF-bRII

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
JP4836451B2 (ja) 2002-07-18 2011-12-14 メルス ベー ヴェー 抗体混合物の組換え生産
CN109485727A (zh) 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
JP5639039B2 (ja) 2008-04-11 2014-12-10 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
EP3456190B1 (de) 2008-06-27 2021-11-24 Merus N.V. Antikörperproduzierende transgene murine tiere
WO2011159877A2 (en) * 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
PT2838917T (pt) 2012-04-20 2019-09-12 Merus Nv Métodos e meios para a produção de moléculas similares a ig heterodiméricas
DK2900694T3 (en) 2012-09-27 2018-11-19 Merus Nv BISPECIFIC IGG ANTIBODIES AS T-CELL ACTIVATORS
WO2015130173A1 (en) * 2014-02-28 2015-09-03 Merus B.V. Antibody that binds erbb-2 and erbb-3
EP3356821B1 (de) * 2015-10-02 2019-10-23 H. Hoffnabb-La Roche Ag Zellbasierter fret-test zum nachweis von simultaner bindung
EP3356411B1 (de) * 2015-10-02 2021-06-30 F. Hoffmann-La Roche AG Bispezifische antikörper für pd1 und tim3
KR20180100305A (ko) * 2015-10-23 2018-09-10 메뤼스 엔.페. 암 성장을 억제하는 결합 분자
AU2016348391A1 (en) * 2015-11-03 2018-05-17 Janssen Biotech, Inc. Antibodies specifically binding TIM-3 and their uses

Also Published As

Publication number Publication date
KR20200042467A (ko) 2020-04-23
MX2020000055A (es) 2020-08-06
US20200216539A1 (en) 2020-07-09
JP7422655B2 (ja) 2024-01-26
BR112020000227A2 (pt) 2020-09-29
EA202090004A1 (ru) 2020-06-18
CN111094348A (zh) 2020-05-01
US20230357407A1 (en) 2023-11-09
AU2018297058B2 (en) 2021-04-29
JP2020532281A (ja) 2020-11-12
IL271832A (en) 2020-02-27
CA3068932A1 (en) 2019-01-10
WO2019009727A1 (en) 2019-01-10
TW201920657A (zh) 2019-06-01
EP3649155A1 (de) 2020-05-13
AU2018297058A1 (en) 2020-01-30
WO2019009727A8 (en) 2020-01-30
US11753470B2 (en) 2023-09-12
PH12020550013A1 (en) 2020-10-12

Similar Documents

Publication Publication Date Title
HK1256365A1 (zh) 對pd1和tim3特異性的雙特異性抗體
IL279235A (en) DLL3-CD3 bispecific antibodies
PL3519437T3 (pl) Przeciwciała dwuswoiste przeciwko p95HER2
ZA201801673B (en) Optimized anti¿cd3 bispecific antibodies and uses thereof
ZA201908549B (en) Checkpoint inhibitor bispecific antibodies
IL271832A (en) Bispecific antibodies against PD1 and against TIM3
EP3487888A4 (de) Bispezifischer anti-her2-antikörper
PL3130606T3 (pl) Przeciwciała dwuswoiste aktywujące układ odpornościowy
GB201710838D0 (en) Bispecific antibodies
EP3507307A4 (de) Bispezifische antikörper
IL262776A (en) Human anti-il-1r3 antibodies
ZA202004908B (en) Bispecific antibody
EP3377112A4 (de) Chemisch blockierte bispezifische antikörper
IL269577B (en) Bispecific antibodies anti–pd–l1–anti–tim–3
IL282355A (en) Bispecific antibodies directed to exosomes
EP3693013A4 (de) Bispezifischer antikörper
SG11201610594WA (en) Anti-il4-il 13 bispecific antibodies
IL274676A (en) The bispecific antigen binding composition
EP3728311A4 (de) Bispezifische hiv-1-neutralisierende antikörper
IL272676B (en) Bispecific antibodies against il-4 and il-13
GB201511196D0 (en) Monoclonal antibodies